KTTA — Pasithea Therapeutics Share Price
0.000.00%
Last trade - 00:00- $5.28m
- -$6.73m
- 18
- 54
- 28
- 25
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.25 | ||
| Price to Tang. Book | 0.46 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -84.29% | ||
| Return on Equity | -54.57% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 0.02 | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- May 19th, 2020
- Public Since
- August 13th, 2021
- No. of Shareholders
- 40
- No. of Employees
- 8
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 1,043,248
- Address
- 1111 Lincoln Road, MIAMI BEACH, 33139
- Web
- https://www.pasithea.com/
- Phone
- +1 7869773380
- Contact
- Lisa Carlton Wilson
- Auditors
- Marcum LLP
Upcoming Events for KTTA
Q2 2024 Pasithea Therapeutics Corp Earnings Release
Similar to KTTA
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Pasithea Therapeutics share price?
As of Today at 22:36 UTC, shares in Pasithea Therapeutics are trading at $4.74. This share price information is delayed by 15 minutes.
How has the Pasithea Therapeutics share price performed this year?
Shares in Pasithea Therapeutics last closed at $4.74 and the price had moved by -45.14% over the past 365 days. In terms of relative price strength the Pasithea Therapeutics share price has underperformed the S&P500 Index by -56.35% over the past year.
What are the analyst and broker recommendations for Pasithea Therapeutics?
The overall consensus recommendation for Pasithea Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Pasithea Therapeutics dividend yield?
Pasithea Therapeutics does not currently pay a dividend.
Does Pasithea Therapeutics pay a dividend?
Pasithea Therapeutics does not currently pay a dividend.
When does Pasithea Therapeutics next pay dividends?
Pasithea Therapeutics does not currently pay a dividend.
How do I buy Pasithea Therapeutics shares?
To buy shares in Pasithea Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Pasithea Therapeutics?
As of the previous close price of $4.74, shares in Pasithea Therapeutics had a market capitalisation of $4.94m.
Where are Pasithea Therapeutics shares listed?
Here are the trading details for Pasithea Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: KTTA
What kind of share is Pasithea Therapeutics?
Based on an overall assessment of its quality, value and momentum Pasithea Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Pasithea Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Pasithea Therapeutics is $2.00. That is 57.81% below the last closing price of $4.74.
Analysts covering Pasithea Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
What is the trend in the Pasithea Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pasithea Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -48.01%.
As of the last closing price of $4.74, shares in Pasithea Therapeutics were trading -37.24% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Pasithea Therapeutics PE Ratio?
The Pasithea Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $4.74.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Pasithea Therapeutics?
We do not have data on Pasithea Therapeutics' directors